PureTech Health plc (NASDAQ:PRTC) Short Interest Down 31.5% in January

PureTech Health plc (NASDAQ:PRTC - Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 24,600 shares, a decrease of 31.5% from the December 31st total of 35,900 shares. Based on an average daily trading volume, of 4,600 shares, the days-to-cover ratio is presently 5.3 days.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 302,000 shares of the company's stock, valued at approximately $5,575,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health as of its most recent SEC filing. 0.04% of the stock is currently owned by institutional investors.

PureTech Health Trading Down 1.5 %

NASDAQ PRTC traded down $0.29 during trading hours on Tuesday, reaching $19.21. 1,376 shares of the company's stock traded hands, compared to its average volume of 3,142. PureTech Health has a 52-week low of $17.00 and a 52-week high of $34.00. The firm has a 50-day simple moving average of $19.70 and a 200 day simple moving average of $20.68.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.